Development of a Score Predicting Survival after Palliative Reirradiation
Table 2
Prognostic factors for survival. All baseline variables shown in Table 1 were analyzed (univariate, log-rank test). Those with value <0.1 were carried forward to multivariate Cox regression analysis and are shown here.
Characteristic
Median survival (months)
value
Univariate1
Multivariate
Karnofsky PS
90–100
18.3
0.0001
0.0001
70–80
9.4
≤60
2.1
Known brain metastases
No
9.7
0.008
n.s.
Yes
3.6
Known liver metastases
No
9.7
0.037
0.039
Yes
2.8
Pleural effusion
No
9.4
0.007
0.039
Yes
1.3
Number of metastatic sites
Max. 2
9.7
0.054
n.s.
3 or more
2.8
Progressive disease outside RT target volume
No
12.6
0.033
n.s.
Yes
5.5
Use of opioid analgetics
No
24.5
0.02
n.s.
Yes
5.2
Use of steroids
No
12.2
0.002
0.015
Yes
3.6
Serum albumin
Low
9.7
0.001
n.s.
Normal
2.8
Serum alkaline phosphatase
Normal
15.1
0.027
n.s.
Elevated
4.1
Serum creatinine
Low
1.6
0.0001
n.s.
Normal
9.7
Elevated
15.1
Serum C-reactive protein
Normal
18.3
0.0001
n.s.
Elevated but less than 30 mg/L
12.6
Elevated 30–60 mg/L
5.3
Elevated >60 mg/L
2.6
Thrombocyte count
Low
12.7
0.038
n.s.
Normal
9.7
High
4.0
Number of abnormal blood tests2
Max. 1
12.7
2
5.8
0.008
n.s.
3 or more
3.0
Smoking status
Current smoker
4.3
0.063
n.s.
No
9.7
Time from first cancer diagnosis
Shorter than median (47 months)
5.3
0.089
n.s.
Longer than median
9.7
RT: radiotherapy; PS: performance status.
1If more than 2 groups, value from log-rank test pooled over all strata.
2All tests shown in Table 1 were considered. Significance levels were not corrected for multiple tests.